Werewolf Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism

 

• Preliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) -

• Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS) or other typically severe IL-2-mediated toxicities -
  
  
• Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the tumor microenvironment (TME) and monotherapy clinical activity in an outpatient setting -
  
  
• Wide therapeutic index supportive of continued dose escalation with cohort 5 (18 mg) fully enrolled and with additional interim data from monotherapy dose escalation arm and recommended dose for expansion arm expected in the first half of 2024 -

Conference Call Information:
Management will host a call to review the preliminary data today, November 3, at 8:30 AM ET. Details for the call can be found here and at https://investors.werewolftx.com/news-and-events/events.

https://www.globenewswire.com/news-release/2023/11/03/2773081/0/en/Werewolf-Therapeutics-Presents-Preliminary-Monotherapy-Data-from-Phase-1-1b-Clinical-Trial-Establishing-Proof-of-Mechanism-for-WTX-124-at-the-Society-for-Immunotherapy-of-Cancer-s-.html